Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of “Buy” from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has been given an average rating of “Buy” by the eight research firms that are presently covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $19.43.

REPL has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. upped their target price on Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. HC Wainwright upped their target price on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, February 13th.

Insider Activity at Replimune Group

In related news, insider Christopher Sarchi sold 3,749 shares of the company’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total value of $30,179.45. Following the sale, the insider now directly owns 128,296 shares of the company’s stock, valued at $1,032,782.80. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Andrew Schwendenman sold 3,287 shares of the company’s stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total value of $26,460.35. Following the completion of the sale, the chief accounting officer now directly owns 68,284 shares in the company, valued at approximately $549,686.20. The trade was a 4.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock worth $603,655 over the last quarter. 8.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC grew its stake in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after acquiring an additional 1,655 shares during the last quarter. US Bancorp DE grew its stake in shares of Replimune Group by 582.6% in the first quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after acquiring an additional 3,921 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock worth $82,000 after acquiring an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd grew its stake in shares of Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock worth $100,000 after acquiring an additional 8,183 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Replimune Group by 106.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company’s stock worth $111,000 after acquiring an additional 5,876 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Stock Performance

Shares of REPL stock opened at $8.93 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. Replimune Group has a fifty-two week low of $4.93 and a fifty-two week high of $17.00. The stock has a 50 day moving average price of $8.39 and a two-hundred day moving average price of $11.09. The company has a market capitalization of $688.39 million, a P/E ratio of -2.91 and a beta of 0.68.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the previous year, the company posted ($0.25) earnings per share. Analysts expect that Replimune Group will post -2.97 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.